Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK

Annals of Oncology

Volumn 21, Issue 7, 2009, Pages 1529-1536

  Logman, J F S ^a   Heeg, B M S ^a   Botteman, M F ^b   Kaura, S ^c   van Hout, B A ^a  

^a PHARMERIT INTERNATIONAL   (Netherlands)

^b PHARMERIT INTERNATIONAL   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

AIBL; Aromatase inhibitor; Bone loss; Breast cancer; Cost effectiveness; Zoledronic acid

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; LETROZOLE; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; FRAGILITY FRACTURE; HEALTH CARE COST; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; INCIDENCE; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; THERAPY DELAY; TREATMENT DURATION; UNITED KINGDOM; VERTEBRA FRACTURE; WRIST FRACTURE;

EID: 77954277190     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp560     Document Type: Article

References (42)

1. Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 2006; 24: 5305-5312.
2. Gibson LJ, Dawson CK, Lawrence DH et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2007; CD003370.
3. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23: 619-629.
4. Eastell R, Hannon RA, Cuzick J et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006; 21: 1215-1223.
5. Coleman RE. ATAC Trialists' Group. Effect of anastrazole on bone mineral density: 5-year results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 2006; 24(18S): 511.
6. Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006; 24: 3629-3635.
7. Geisler J, Lonning PE, Krag LE et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 2006; 42: 2968-2975.
8. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
9. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492.
10. Goss PE, ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262-1271.
11. Bell R, Sambrook P, Chen Z et al. Relative risk for fractures in postmenopausal women, postmenopausal breast cancer survivors and postmenopausal women managed with adjuvant hormonal therapy. Eur J Cancer Suppl 2006; 4(2): S95.
12. Chen Z, Maricic M, Bassford TL et al. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 2005; 165: 552-558.
13. Brufsky AM. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist 2008; 13: 187-195.
14. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042-4057.
15. Brufsky A, Harker WG, Beck JT et al. Zoledronic acid inhibits adjuvant letrozoleinduced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25: 829-836.
16. Bundred NJ, Campbell ID, Davidson N et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 2008; 112: 1001-1010.
17. De Boer R, Eidtmann H, Lluch A et al. The ZO-FAST trial: zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24month BMD results. Breast Cancer Res Treat 2007; 106 (Suppl 1): S36.
18. Eidtmann H, Bundred NJ, De Boer R et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving letrozole: 36 months follow-up of ZO-FAST. In 31st Annual San Antonio Breast Cancer Symposium. San Antonio, TX 2008.
19. Dolan P, Torgerson D. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 2000; 11: 551-552.
20. Empana JP, Dargent-Molina P, Breart G. Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. J Am Geriatr Soc 2004; 52: 685-690.
21. Robbins JA, Biggs ML, Cauley J. Adjusted mortality after hip fracture: from the cardiovascular health study. J Am Geriatr Soc 2006; 54: 1885-1891.
22. Cancer Research UK. UK Breast Cancer Incidence Statistics Trends. http://info.cancerresearchuk.org/cancerstats/types/breast/incidence/ (27 November 2009, date last accessed).
23. Stevenson M, Lloyd JM, De NE et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005; 9: 1-160.
24. Klotzbuecher CM, Ross PD, Landsman PB et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15: 721-739
25. Goldhirsch A, ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.
26. Hadji P, Body JJ, Aapro MS et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008; 19: 1407-1416.
27. Body JJ, Bergmann P, Boonen S et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer-a consensus paper of the Belgian Bone Club. Osteoporos Int 2007; 18: 1439-1450.
28. Kanis JA, Johnell O, Oden A et al. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 2000; 27: 585-590.
29. Truscott JG, Simpson DS, Fordham JN. A suggested methodology for the construction of national bone densitometry reference ranges: 1372 Caucasian women from four UK sites. Br J Radiol 1997; 70: 1245-1251.
30. Chen Z, Maricic M, Pettinger M et al. Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Cancer 2005; 104: 1520-1530.
31. De Laet CE, van Hout BA, Burger H et al. Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 1997; 315: 221-225.
32. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254-1259.
33. Johnell O, Kanis JA, Oden A et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20: 1185-1194.
34. The United Kingdom Government Actuary's Department (GAD). UK Female Interim Life Tables 2003-2005. London: Office for National Statistics 2007.
35. Gloeckler Ries LA, Reichman ME, Lewis DR et al. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003; 8: 541-552.
36. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. London: BMJ Publishing Group Ltd & the Royal Pharmaceutical Society of Great Britain 2005.
37. Botteman M, Barghout V, Stephens J et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006; 17: 1072-1082.
38. Stevenson MD, Davis SE, Kanis JA. The hospitalisation costs and out-patient costs of fragility fractures. Women's Health Medicine 2006; 3: 149-151.
39. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. London: National Institute for Clinical Excellence 2004.
40. Kanis JA, Johnell O, Oden A et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int 2004; 15: 20-26.
41. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001; 323: 1300-1303.
42. Reid DM, Doughty J, Eastell R et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008; 34 (Suppl 1): S3-S18